1
|
Langeveld SAG, Meijlink B, Beekers I, Olthof M, van der Steen AFW, de Jong N, Kooiman K. Theranostic Microbubbles with Homogeneous Ligand Distribution for Higher Binding Efficacy. Pharmaceutics 2022; 14:pharmaceutics14020311. [PMID: 35214044 PMCID: PMC8878664 DOI: 10.3390/pharmaceutics14020311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 01/14/2022] [Accepted: 01/16/2022] [Indexed: 02/05/2023] Open
Abstract
Phospholipid-coated targeted microbubbles are used for ultrasound molecular imaging and locally enhanced drug delivery, with the binding efficacy being an important trait. The use of organic solvent in microbubble production makes the difference between a heterogeneous or homogeneous ligand distribution. This study demonstrates the effect of ligand distribution on the binding efficacy of phospholipid-coated ανβ3-targeted microbubbles in vitro using a monolayer of human umbilical-vein endothelial cells and in vivo using chicken embryos. Microbubbles with a homogeneous ligand distribution had a higher binding efficacy than those with a heterogeneous ligand distribution both in vitro and in vivo. In vitro, 1.55× more microbubbles with a homogeneous ligand distribution bound under static conditions, while this was 1.49× more under flow with 1.25 dyn/cm2, 1.56× more under flow with 2.22 dyn/cm2, and 1.25× more in vivo. The in vitro dissociation rate of bound microbubbles with homogeneous ligand distribution was lower at low shear stresses (1–5 dyn/cm2). The internalized depth of bound microbubbles was influenced by microbubble size, not by ligand distribution. In conclusion, for optimal binding the use of organic solvent in targeted microbubble production is preferable over directly dispersing phospholipids in aqueous medium.
Collapse
Affiliation(s)
- Simone A. G. Langeveld
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
- Correspondence:
| | - Bram Meijlink
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
| | - Inés Beekers
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
- Department of Health, ORTEC B.V., 2719 EA Zoetermeer, The Netherlands
| | - Mark Olthof
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
| | - Antonius F. W. van der Steen
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
| | - Nico de Jong
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
- Imaging Physics, Delft University of Technology, 2628 CJ Delft, The Netherlands
| | - Klazina Kooiman
- Thorax Center, Biomedical Engineering, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; (B.M.); (I.B.); (M.O.); (A.F.W.v.d.S.); (N.d.J.); (K.K.)
| |
Collapse
|
2
|
Phospholipid-coated targeted microbubbles for ultrasound molecular imaging and therapy. Curr Opin Chem Biol 2021; 63:171-179. [PMID: 34102582 DOI: 10.1016/j.cbpa.2021.04.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 04/26/2021] [Accepted: 04/27/2021] [Indexed: 01/24/2023]
Abstract
Phospholipid-coated microbubbles are ultrasound contrast agents that, when functionalized, adhere to specific biomarkers on cells. In this concise review, we highlight recent developments in strategies for targeting the microbubbles and their use for ultrasound molecular imaging (UMI) and therapy. Recently developed novel targeting strategies include magnetic functionalization, triple targeting, and the use of several new ligands. UMI is a powerful technique for studying disease progression, diagnostic imaging, and monitoring of therapeutic responses. Targeted microbubbles (tMBs) have been used for the treatment of cardiovascular diseases and cancer, with therapeutics either coadministered or loaded onto the tMBs. Regardless of which disease was treated, the use of tMBs always resulted in a better therapeutic outcome than non-tMBs when compared in vitro or in vivo.
Collapse
|
3
|
Deprez J, Lajoinie G, Engelen Y, De Smedt SC, Lentacker I. Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery. Adv Drug Deliv Rev 2021; 172:9-36. [PMID: 33705877 DOI: 10.1016/j.addr.2021.02.015] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 02/01/2021] [Accepted: 02/17/2021] [Indexed: 12/13/2022]
Abstract
Apart from its clinical use in imaging, ultrasound has been thoroughly investigated as a tool to enhance drug delivery in a wide variety of applications. Therapeutic ultrasound, as such or combined with cavitating nuclei or microbubbles, has been explored to cross or permeabilize different biological barriers. This ability to access otherwise impermeable tissues in the body makes the combination of ultrasound and therapeutics very appealing to enhance drug delivery in situ. This review gives an overview of the most important biological barriers that can be tackled using ultrasound and aims to provide insight on how ultrasound has shown to improve accessibility as well as the biggest hurdles. In addition, we discuss the clinical applicability of therapeutic ultrasound with respect to the main challenges that must be addressed to enable the further progression of therapeutic ultrasound towards an effective, safe and easy-to-use treatment tailored for drug delivery in patients.
Collapse
Affiliation(s)
- J Deprez
- Ghent Research Group on Nanomedicines, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - G Lajoinie
- Physics of Fluids Group, MESA+ Institute for Nanotechnology and Technical Medical (TechMed) Center, University of Twente, P.O. Box 217, 7500 AE Enschede, Netherlands
| | - Y Engelen
- Ghent Research Group on Nanomedicines, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - S C De Smedt
- Ghent Research Group on Nanomedicines, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
| | - I Lentacker
- Ghent Research Group on Nanomedicines, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| |
Collapse
|